Corporate News: Scandium International Mining Corp – A Snapshot of Recent Performance
Scandium International Mining Corp (ticker SCY.V) experienced a pronounced decline in its share price during the 24‑hour trading window that closed at 11:39 AM Central Europe on Friday, 23 October 2026. The stock fell 9.52 %, trading at approximately CAD 0.10 per share on the principal exchanges.
Market Context
- Shares Outstanding: 357.5 million
- Market Capitalisation: CAD 34 million
- Average Trading Volume (last 24 h): CAD 89.3 k
- Trailing 200‑day Simple Moving Average: CAD 0.14
- 52‑Week High: CAD 0.18 (11 September 2026)
- 52‑Week Low: CAD 0.08 (11 February 2026)
Since the close of the previous month, the share price has decreased by 42.42 %, underscoring a broader downturn in the company’s valuation over the past month.
Comparative Performance of Peer Companies
| Stock | 24‑h Movement | Current Price | Market Capitalisation |
|---|---|---|---|
| Microcloud Hologram (HOLO) | –0.79 % | USD 1.21 | USD 28.6 million |
| Innventure (INV) | +17.59 % | USD 0.33 | USD 28.9 million |
| Mira (MIRA) | +4.92 % | USD 0.63 | USD 28.7 million |
| Pioneer Power (PPSI) | –8.63 % | USD 2.33 | USD 28.3 million |
| Cel‑Sci (CVM) | –0.62 % | USD 1.61 | USD 28.5 million |
The performance of these peers illustrates the volatility in the broader specialty‑metals and technology sectors, with only Innventure achieving a notable gain in the past 24 hours.
Notable Developments in the MIRA Portfolio
MIRA Pharmaceuticals, Inc. recently announced the outcomes of a 21‑day preclinical study for its lead candidate MIRA‑55, an oral synthetic cannabinoid analogue targeting chronic inflammatory pain. Key findings include:
- Significant reduction in mechanical and thermal pain sensitivity, comparable to the NSAID celecoxib.
- Sustained pain relief without tolerance development.
- Decrease in inflammation‑associated swelling.
- No adverse clinical signs across both male and female animal cohorts.
These results reinforce MIRA’s strategy to progress MIRA‑55 within its IND‑enabling development program, with an investigational new drug submission anticipated in the first quarter of 2027. The company remains focused on advancing a pipeline of pain‑focused candidates, positioning itself for long‑term therapeutic options in neuropathic and inflammatory pain disorders.
Company Overview
Scandium International Mining Corp, headquartered in Sparks, United States, specialises in exploration and acquisition services for specialty metals such as tungsten, vanadium, molybdenum, and uranium. Operating throughout North America, Scandium provides tailored solutions for clients seeking access to high‑value mineral resources. The company went public on the Toronto Stock Exchange on 24 April 2008. For further details on its services, initiatives, and corporate governance, visit the official website at www.scandiummining.com .